Company Analysis

AIM ImmunoTech Inc. (AIM)

NYSE: AIM · Biological Products, (No Diagnostic Substances) · Ocala, FL · filing with the SEC since 1996
Grade3.3
◀ Past 2.6● Present 3.7▶ Future 3.4
2 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedMar 27, 2026Mar 27, 2025Apr 1, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 30, 2020Apr 1, 2019Mar 30, 2018Mar 31, 2017
Revenue8817020214113516314036743792
Research and development3,9246,19710,9396,9907,6725,7204,6514,7784,0985,107
General and administrative7,70013,71421,13713,0748,6728,6547,0396,2016,5727,681
Total costs and expenses11,75219,94232,11820,06418,97315,31512,58311,86311,85313,896
Operating income-11,664-19,772-31,916-19,923-18,838-15,152-12,443-11,496-11,416-13,804
Interest expense812585··67672427201··
Other income (expense), net3,1835,1921,069629······
Income before income taxes-13,958·········
Net income-13,958-17,320-28,962-19,445-19,127-14,400-9,404r-9,827r-8,259-7,502
Earnings per share, basic-8.62-30.92r-60.00b-40.00b-40.00b·····
Earnings per share, diluted-8.62-30.92r-60.00b-40.00b······
Earnings per share, basic and diluted····-40.00b-45.00b-258.00rb-977.00rb-29.00b-34.00b
Weighted average shares, basic1,618,617560,169r485,854b·······
Weighted average shares, diluted1,618,617560,169r485,854b480,473b······
Weighted average shares, basic and diluted····473,400b318,428b36,427b10,043rb286,761b218,182b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-100 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
us-gaap:SalesRevenueNet
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton AIM · research, not advice